Status message

Active context: kki_bg_colors_yellow

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study To Evaluate The Efficacy And Safety Of Lurasidone In Children And Adolescent Subjects With Bipolar I Depression

Principal Investigator:
Robert
Findling

To evaluate the efficacy of lurasidone (20 - 80 mg/day flexibly dosed) compared with placebo in children and adolescent subjects with bipolar I disorder, most recent episode depressed, with or without rapid cycling disease course, and without psychotic features (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. [DSM-V] criteria) as measured by the change from Baseline in the Children's Depression Rating Scale, Revised (CDRS-R) total score.

March is Brain Injury Awareness Month

Brain Injury Awareness Month

Help raise awareness and support for brain injury research, treatment and education. Learn more about our program.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.